D. Maitland

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

B. Gazzard, M. Boffito, M. Nelson, 2005, AIDS.

Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies

M. Boffito, A. Pozniak, D. Maitland, 2006, Journal of clinical pharmacology.

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

B. Gazzard, S. Khoo, J. Ford, 2006, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

B. Gazzard, M. Boffito, D. Back, 2006, AIDS research and human retroviruses.

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

B. Gazzard, M. Boffito, D. Back, 2005, The Journal of antimicrobial chemotherapy.

Tenofovir and didanosine: a dangerous liaison.

L. Waters, G. Moyle, D. Maitland, 2005, The AIDS reader.

The pharmacokinetics of HIV protease inhibitor combinations

M. Boffito, A. Pozniak, D. Maitland, 2005, Current opinion in infectious diseases.

Switching from twice‐daily abacavir and lamivudine to the once‐daily fixed‐dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

B G Gazzard, B. Gazzard, G. Moyle, 2008, HIV medicine.